Back to News
Market Impact: 0.42
Pharming Gets FDA Approval For Joenja In Children With APDS
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Pharming Group said the FDA approved Joenja (leniolisib) for APDS patients aged 4 to 11 who weigh at least 27 kg. The expanded pediatric indication broadens the addressable population for the rare-disease therapy and is a meaningful positive regulatory catalyst for Pharming.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
PHAR0.82
More News
- FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
- Apollo in talks to buy J&J orthopedics unit for nearly $20 billion
- Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports
- US legislators push AI safety laws amid human extinction warnings
- Flavio Bolsonaro faces corruption probe weeks before Brazil election
- Federal budget deficit reaches $2T in first 11 months of fiscal year 2026, CBO reports